Health TrialsbyHealthPanel

Tumor Infiltrating Lymphocyte

3

Review clinical trials related to Tumor Infiltrating Lymphocyte. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With

To find out if the amount of CD8 immune cells at the place where TIL cells are collected is linked to how well a patient responds to treatment.

Participants needed: 6
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Sep 15, 2026Locations: 1
Eligibility criteria

Participants must have histologically confirmed advanced melanoma and have been... [+9]

Participants who are not eligible and consented for standard-of-care Iovance TIL... [+4]

Read more
Status: Recruiting

A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced hepatobiliary-pancreatic cancers. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Participants needed: 50
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Juncell TherapeuticsUpdated: Dec 11, 2025Locations: 1
Eligibility criteria

Age: 18 years to 75 years; [+21]

Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (o... [+12]

Read more
Status: Recruiting

A Study of GC101 TIL in Advanced Melanoma (10hospital)

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Participants needed: 50
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Juncell TherapeuticsUpdated: Dec 11, 2025Locations: 1
Eligibility criteria

Age: 18 years to 75 years; [+21]

Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (o... [+12]

Read more